CA3263043A1 - Inhibiteurs de jak1/jak2/tyk2 pour le traitement topique de maladies dermatologiques - Google Patents

Inhibiteurs de jak1/jak2/tyk2 pour le traitement topique de maladies dermatologiques

Info

Publication number
CA3263043A1
CA3263043A1 CA3263043A CA3263043A CA3263043A1 CA 3263043 A1 CA3263043 A1 CA 3263043A1 CA 3263043 A CA3263043 A CA 3263043A CA 3263043 A CA3263043 A CA 3263043A CA 3263043 A1 CA3263043 A1 CA 3263043A1
Authority
CA
Canada
Prior art keywords
jak1
jak2
topical treatment
dermatological diseases
tyk2 inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3263043A
Other languages
English (en)
Inventor
Congxin Liang
Shuangjiang LI
Xiaojing Tang
Junmin Huang
Original Assignee
Hangzhou Highlightll Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Highlightll Pharmaceutical Co Ltd filed Critical Hangzhou Highlightll Pharmaceutical Co Ltd
Publication of CA3263043A1 publication Critical patent/CA3263043A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3263043A 2022-08-22 2023-08-10 Inhibiteurs de jak1/jak2/tyk2 pour le traitement topique de maladies dermatologiques Pending CA3263043A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022113873 2022-08-22
CNPCT/CN2022/113873 2022-08-22
PCT/CN2023/112361 WO2024041397A1 (fr) 2022-08-22 2023-08-10 Inhibiteurs de jak1/jak2/tyk2 pour le traitement topique de maladies dermatologiques

Publications (1)

Publication Number Publication Date
CA3263043A1 true CA3263043A1 (fr) 2024-02-29

Family

ID=90012519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3263043A Pending CA3263043A1 (fr) 2022-08-22 2023-08-10 Inhibiteurs de jak1/jak2/tyk2 pour le traitement topique de maladies dermatologiques

Country Status (8)

Country Link
EP (1) EP4577535A1 (fr)
JP (1) JP2025529836A (fr)
KR (1) KR20250051678A (fr)
AU (1) AU2023328280A1 (fr)
CA (1) CA3263043A1 (fr)
IL (1) IL318535A (fr)
MX (1) MX2025002033A (fr)
WO (1) WO2024041397A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104849C2 (uk) * 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
JP2014500254A (ja) * 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
WO2014111037A1 (fr) * 2013-01-18 2014-07-24 上海昀怡健康管理咨询有限公司 Composé hétérocyclique à cinq et six chaînons, procédé de préparation, composition pharmaceutique et application associés
WO2020118683A1 (fr) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
CN110862380A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN110862376A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN114181199B (zh) * 2020-09-15 2023-09-26 成都赜灵生物医药科技有限公司 2，4-二取代嘧啶衍生物及其制备方法和用途
AU2022361055A1 (en) * 2021-10-06 2024-04-04 Alcon Inc. Janus kinase inhibiting pyrazole compounds and uses thereof

Also Published As

Publication number Publication date
MX2025002033A (es) 2025-04-02
EP4577535A1 (fr) 2025-07-02
IL318535A (en) 2025-03-01
KR20250051678A (ko) 2025-04-17
AU2023328280A1 (en) 2025-02-13
WO2024041397A1 (fr) 2024-02-29
JP2025529836A (ja) 2025-09-09

Similar Documents

Publication Publication Date Title
WO2024167922A3 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de nras
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
CA3263467A1 (fr) Composés pour le traitement d'états pathologiques et de maladies
AU2024216821A1 (en) Rifabutin analogs for the treatment of bacterial diseases
HK40128871A (en) Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
CA3263043A1 (fr) Inhibiteurs de jak1/jak2/tyk2 pour le traitement topique de maladies dermatologiques
CA3263211A1 (fr) Utilisations thérapeutiques de dérivés d'urolithine
HK40101808A (en) Jak1 pathway inhibitors for the treatment of vitiligo
CA3286233A1 (fr) Inhibiteurs de la voie jak1 pour le traitement de l'asthme
AU2025902087A0 (en) Anthelmintic compounds and methods of manufacture and therapeutic use
CA3283887A1 (fr) Thérapie génique pour le traitement de la douleur
AU2026901172A0 (en) Treatment of metabolic diseases
CA3297910A1 (fr) Utilisation thérapeutique de fibroblastes pour le traitement du psoriasis
AU2022900189A0 (en) Anthelmintic compounds and methods of manufacture and therapeutic use
CA3296699A1 (fr) Composés de pyridazine substitués utilisés en tant qu'inhibiteurs de l'activité de nlrp3 et leurs utilisations thérapeutiques
AU2024309802A1 (en) Substituted pyridazine compounds as inhibitors of nlrp3 activity and therapeutic uses thereof
HK40101476A (en) Microdystrophin gene therapy administration for treatment of dystrophinopathies
CA3271575A1 (fr) Inhibiteurs de cxcr4 pour le traitement de maladies neurologiques
HK40124203A (en) Compound for treatment of pain
CA3268988A1 (fr) Composé pour le traitement de la douleur
CA3273902A1 (fr) Inhibiteurs de jak2
CA3295825A1 (fr) Nouveaux composés pour traiter le cancer et des maladies métaboliques
CA3295889A1 (fr) Nouveaux composés pour traiter le cancer et des maladies métaboliques
CA3278922A1 (fr) Analogues de rifabutine pour le traitement de maladies bactériennes
CA3282562A1 (fr) Administration topique d'oligonucléotides thérapeutiques

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250123

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250123

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250429

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250429

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250508

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250508

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250508

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250517